美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Array Digital Infrastructure Inc.

38.28

+0.16000.42%

盤後：38.280.00000.00%19:30 EDT

成交量：26.80萬

成交額：1,022.12萬

市值：33.07億

市盈率：6.19

高：38.37

開：38.07

低：37.85

收：38.12

52周最高：60.82

52周最低：33.71

股本：8,637.99萬

流通股本：1,556.33萬

量比：1.03

換手率：1.72%

股息：- -

股息率：- -

每股收益(TTM):6.19

每股收益(LYR):0.5551

淨資產收益率：22.68%

總資產收益率：0.02%

市淨率：2.61

市盈率(LYR):68.97

資料載入中...

總覽公司新聞資訊公告

Digitus集團子公司與迪拜Du簽署託管服務協議附錄

康哲百盧妥獲批，特應性皮炎治療版圖正在重構

Digitus集團任命Kunal Dalmia為集團首席財務官

康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批

Digitus集團宣佈首席財務官Wissam Farhat辭職

美國研究綜述-Cogent Communications、Dollar Tree、家得寶

科威特Digitus集團Q2淨虧損74.023萬第納爾

新股前瞻|探索活菌治病潛力，知易生物稀缺管線看點幾何？

邁克生物：AD檢測試劑目前收入貢獻不大

財報前瞻｜Array Digital Infrastructure Inc.本季度營收預計降94.24%，機構觀點趨於謹慎

Alamar Biosciences 推出首款血液多重免疫檢測，用於檢測 eMTBR-Tau，它是阿茲海默症研究中最重要生物標記之一

GENMA獲AD Ports集團8台RTG訂單

國金證券：長效AD產品價值進一步獲得MNC驗證維持康諾亞-B(02162)「買入」評級

港股異動 | 康諾亞-B(02162)早盤升逾6% 艾伯維斥資超百億美元收購Apogee 長效AD產品獲MNC驗證

美國研究綜述-阿波羅、菲利普斯66、瓦萊羅能源

腦機接口尚處早期 AD藥效待突破！下一個醫藥爆款在何處？

21世纪经济报道

Digitus集團一季度淨虧損46.071萬第納爾

衞材預計阿爾茨海默病突破性藥物Leqembi26財年全球銷售額將達1435億日元

專訪復星國際陳啓宇：拿下AD新藥全球權益，「造船出海」正當時

21世纪经济报道

復星醫藥加碼早期AD口服藥，董事長陳玉卿：看好AD賽道潛力，將做好全球商業化準備

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/AD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":38.28,"timestamp":1789416000000,"preClose":38.12,"halted":0,"volume":267965,"hourTrading":{"tag":"盘后","latestPrice":38.28,"preClose":38.28,"latestTime":"19:30 EDT","volume":23110,"amount":884650.8,"timestamp":1789428606191,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0041972717733474215,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"未開盤","change":0.16,"latestTime":"09-14 16:00:00 EDT","open":38.07,"high":38.37,"low":37.845,"amount":10221189.96875,"amplitude":0.013772,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":38.12,"postHourTrading":{"tag":"盘后","latestPrice":38.28,"preClose":38.28,"latestTime":"19:30 EDT","volume":23110,"amount":884650.8,"timestamp":1789428606191,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.034715,"impliedVol":0.3173,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":1.034715,"shares":86379877,"dividePrice":0,"high":38.37,"amplitude":0.013772,"preClose":38.12,"low":37.845,"week52Low":33.71,"pbRate":"2.61","psRate":"15.49","week52High":60.82,"institutionHeld":0.3358,"latestPrice":38.28,"eps":6.185934,"divideRate":0,"volume":267965,"delay":0,"ttmEps":6.185934,"open":38.07,"prevYearClose":53.62,"prevWeekClose":38.12,"prevMonthClose":36.66,"prevQuarterClose":36.26,"fiveDayClose":38.5,"twentyDayClose":35.98,"sixtyDayClose":39.01,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"盤前","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"盤前","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"盤前","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-09-11","current":6.188233,"percent":0.3,"low":-273.92211,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"high":320.844562,"avg":57.30785,"sd":169.935215,"marketCap":3290525950},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710},{"date":"2026-09-04","current":6.254541,"twenty":-175.112012,"median":21.259662,"eighty":260.252418,"marketCap":3349331670},{"date":"2026-09-11","current":6.144727,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"marketCap":3290525950}],"updateTime":1789419552194},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1179527322","title":"Digitus集團子公司與迪拜Du簽署託管服務協議附錄","url":"https://stock-news.laohu8.com/highlight/detail?id=1179527322","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179527322?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:07","pubTimestamp":1789380463,"startTime":"0","endTime":"0","summary":"9月14日（路透社）—— DIGITUS GROUP FOR DIGITAL INFRASTRUCTURE, DATA CENTERS & COMMUNICATIONS KSCP宣布，其阿联酋子公司已与Du签署现有托管服务协议的附录。该附录涵盖主要现场维护服务、数据中心及网络站点运维服务的延期。\n此补充协议的总价值为6380万阿联酋迪拉姆，有效期为一年。Digitus集团表示，此次合作将进一步巩固其在数字基础设施领域的市场地位。\n更多公司资讯，请关注DIGITUS.KW后续报道。（完）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538767","title":"康哲百盧妥獲批，特應性皮炎治療版圖正在重構","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538767","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538767?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:32","pubTimestamp":1788953520,"startTime":"0","endTime":"0","summary":"9月2日，康哲药业旗下德镁医药的磷酸芦可替尼乳膏获NMPA批准新增特应性皮炎适应症征，用于其他外用药控制不佳或不建议使用时、非免疫功能受损的2岁及以上儿童和成人轻中度AD的局部短期和非持续性慢性治疗，9月3日药品注册证书核发。这是磷酸芦可替尼乳膏继今年1月获批白癜风之后，在国内拿下的第二个适应征。从激素到达必妥，从口服JAK到外用靶向乳膏，5400万中国患者的治疗选择，正在以前所未有的速度变厚。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-09/doc-inirfums3607144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TCS","AD","BK4200","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125161320","title":"Digitus集團任命Kunal Dalmia為集團首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=1125161320","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125161320?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:28","pubTimestamp":1788953328,"startTime":"0","endTime":"0","summary":"9月9日电——数字基础设施、数据中心与通信领域的Digitus集团今日宣布一项重要人事任命。Kunal Dalmia将正式出任集团首席财务官一职，此举标志着该公司在财务管理层面迈出关键一步。\nDigitus集团专注于数字基础设施建设、数据中心运营及相关通信服务，此次人事变动正值公司业务持续扩张之际。Dalmia的加入，预计将为集团财务战略注入新的视角与管理经验。\n关于此项任命的更多细节，公司暂未披露其他相关变动。相关后续报道将持续跟进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","BK4132","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875311","title":"康哲藥業(00867)：創新藥磷酸蘆可替尼乳膏百盧妥®增加特應性皮炎適應症(AD) 中國上市許可申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875311?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 18:01","pubTimestamp":1788429695,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司已于2026年9月2日获得中国国家药品监督管理局批准磷酸芦可替尼乳膏百卢妥轻中度特应性皮炎的新药上市许可申请，并于2026年九月3日获得药品注册证书。2026年1月，百卢妥中国NDA获批，成为中国批准的首款用于白癜风治疗的外用 JAK抑制剂。继百卢妥获批白癜风适应症后，此次AD适应症NDA获批，将进一步拓展产品的临床应用空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","159992","BK4132","IPOS","IE00BMCWC346.EUR","06978","IE00BGHQDM52.EUR","AD","00867","MEDX","BK1191","SG9999015986.USD","SG9999015978.USD","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","SG9999015952.SGD","BK1574","SG9999004220.SGD","BK1593","BK1161","IE00BYV24P56.USD","LU2488822045.USD","IBBQ","SG9999015945.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120950813","title":"Digitus集團宣佈首席財務官Wissam Farhat辭職","url":"https://stock-news.laohu8.com/highlight/detail?id=1120950813","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120950813?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 19:59","pubTimestamp":1787745596,"startTime":"0","endTime":"0","summary":"8月26日（路透社）——数字基础设施、数据中心与通信领域的Digitus集团今日发布重要人事变动消息。该公司宣布，Wissam Farhat已辞去首席财务官一职，该决定将于8月31日正式生效。\n这一高层人事调整来得颇为突然，市场对此保持高度关注。Digitus集团并未在公告中详细说明Farhat离职的具体原因，也未透露继任者的安排计划。\n作为专注于数字基础设施领域的企业，Digitus集团的财务掌门人变动，无疑将为公司未来的战略规划和财务决策带来一定的不确定性。投资者和分析师们正密切关注这一变动可能对公司带来的潜在影响。\n有关该公司的更多报道，请持续关注后续动态。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","TDS","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660443846","title":"美國研究綜述-Cogent Communications、Dollar Tree、家得寶","url":"https://stock-news.laohu8.com/highlight/detail?id=2660443846","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660443846?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 15:51","pubTimestamp":1787125868,"startTime":"0","endTime":"0","summary":"美国研究综述-Cogent Communications、Dollar Tree、家得宝路透8月19日-周三，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括Cogent Communications、Dollar Tree和The Home Depot。要点* 科根特通信控股公司CCOI.O：摩根大通将评级从“中性”下调至“减持”* 美元树公司DLTR.O：杰富瑞将评级从“跑输大盘”上调至“持有”* 家得宝公司HD.N：杰富瑞将目标价从360美元上调至398美元以下是路透周三报道的关于美国公司的研究报告摘要。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4S44G0KK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BZZ","GPN","TBLU","TRUM","HD","ARMK","AD","TDS","BAND","CCOI","ZAP","ECL","CAH","COR","IDEF","FSPC","LU1989772923.USD","PKB","WDGF","NUKX","MNSH","BK4550","LU0823411888.USD","HOMZ","NOC","D","SHLD","CGW","FOWF","AMLX","BPAY","LU0154236417.USD","MD","DLTR","LU2125909916.SGD","LU1923622614.USD","MCK","KEYS","RSPS","LU1596574779.USD","LU2413666004.HKD","EVX","LU1084165304.USD","MRCY","ELF","LU0124676726.USD","RTH","BK4109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163001684","title":"科威特Digitus集團Q2淨虧損74.023萬第納爾","url":"https://stock-news.laohu8.com/highlight/detail?id=1163001684","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163001684?lang=zh_tw&edition=fundamental","pubTime":"2026-08-16 14:07","pubTimestamp":1786860450,"startTime":"0","endTime":"0","summary":"8月16日，路透社消息——科威特数字基础设施、数据中心与通信领域的Digitus集团公布其二季度财务报告。\n数据显示，该集团在第二季度归属股东净亏损达到74.023万第纳尔。与此同时，其二季度总营业收入为690万第纳尔。\n更多公司详情可关注：DIGITUS.KW","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","TDS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656504559","title":"新股前瞻|探索活菌治病潛力，知易生物稀缺管線看點幾何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2656504559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656504559?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 20:32","pubTimestamp":1785846730,"startTime":"0","endTime":"0","summary":"截至2026年4月30日，公司账上现金及现金等价物为4906.5万元，且无银行贷款。公司预计SK08的III期临床将于2027年第三季度完成入组，第四季度完成主要疗效终点评估，2028年下半年提交NDA。目前SK10已在美国完成I期临床，50%受试者为华裔，所有不良事件均为轻度，未发生中度或重度事件及严重不良事件，安全性与耐受性良好。然而，即便SK08临床进展顺利，知易生物要实现从研发到商业化的跨越，仍面临多重挑战。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475959.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CID","BK4132","OM","IPOS","BK4082","IBBQ","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656983317","title":"邁克生物：AD檢測試劑目前收入貢獻不大","url":"https://stock-news.laohu8.com/highlight/detail?id=2656983317","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656983317?lang=zh_tw&edition=fundamental","pubTime":"2026-08-02 18:07","pubTimestamp":1785665255,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145776153","title":"財報前瞻｜Array Digital Infrastructure Inc.本季度營收預計降94.24%，機構觀點趨於謹慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1145776153","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145776153?lang=zh_tw&edition=fundamental","pubTime":"2026-08-01 00:08","pubTimestamp":1785514115,"startTime":"0","endTime":"0","summary":"Array Digital Infrastructure Inc.将于2026年08月07日盘前发布财报，市场关注营收与每股收益的同比变动与结构性驱动因素。市场一致预期本季度营收为5,250.28万美元，同比下降94.24%；调整后每股收益为0.62美元，同比增长110.17%；息税前利润为360.93万美元，同比下降92.30%；上季度未披露关于本季度毛利率、净利润或净利率的具体预测。上一季度公司营收为5,201.20万美元，同比下降94.16%；毛利率为58.45%；归属于母公司股东的净利润为1.78亿美元，净利率为341.83%；调整后每股收益为1.67美元，同比增长696.19%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Array Digital Infrastructure Inc.本季度营收预计降94.24%，机构观点趋于谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649896344","title":"Alamar Biosciences 推出首款血液多重免疫檢測，用於檢測 eMTBR-Tau，它是阿茲海默症研究中最重要生物標記之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2649896344","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649896344?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 09:55","pubTimestamp":1783475700,"startTime":"0","endTime":"0","summary":"本新闻稿中的任何前瞻性陈述皆基于 Alamar Biosciences 目前的预期，并涉及可能永远不会实现或最终被证实不正确的假设。谨此提醒读者，实际结果可能因各种风险与不确定性而与 Alamar Biosciences 的前瞻性陈述所明示或暗示者有重大差异。Alamar Biosciences 明确声明，除法律要求外，概不承担更新任何前瞻性陈述的责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3323782/0/zh-hant/Alamar-Biosciences-%E6%8E%A8%E5%87%BA%E9%A6%96%E6%AC%BE%E8%A1%80%E6%B6%B2%E5%A4%9A%E9%87%8D%E5%85%8D%E7%96%AB%E6%AA%A2%E6%B8%AC-%E7%94%A8%E6%96%BC%E6%AA%A2%E6%B8%AC-eMTBR-Tau-%E5%AE%83%E6%98%AF%E9%98%BF%E8%8C%B2%E6%B5%B7%E9%BB%98%E7%97%87%E7%A0%94%E7%A9%B6%E4%B8%AD%E6%9C%80%E9%87%8D%E8%A6%81%E7%94%9F%E7%89%A9%E6%A8%99%E8%A8%98%E4%B9%8B%E4%B8%80.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","AD","AAIC","BK4132","IE00B3T34201.USD","BK4585","LU0225771236.USD","LU0321505439.SGD","LU0985481810.HKD","LU0225284248.USD","LU0321505868.SGD","TAP","BK4158","BK4588","LU0306806265.USD","BK4110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648542146","title":"GENMA獲AD Ports集團8台RTG訂單","url":"https://stock-news.laohu8.com/highlight/detail?id=2648542146","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648542146?lang=zh_tw&edition=fundamental","pubTime":"2026-07-03 16:32","pubTimestamp":1783067522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645600470","title":"國金證券：長效AD產品價值進一步獲得MNC驗證 維持康諾亞-B(02162)「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2645600470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645600470?lang=zh_tw&edition=fundamental","pubTime":"2026-06-23 10:42","pubTimestamp":1782182527,"startTime":"0","endTime":"0","summary":"长效AD产品价值或将进一步获MNC验证AD患者治疗周期长、复发率高，疗效和给药便利性对患者而言至关重要，因此在疗效接近或具备非劣基础上，若能实现更低频给药，产品有望在维持治疗和商业化竞争中形成明显优势。Apogee的IL-13长效抗体获得MNC艾伯维青睐，说明MNC对长效AD资产的战略价值和峰值销售潜力给予厚望，长效AD产品价值进一步获得MNC验证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001593","title":"港股異動 | 康諾亞-B(02162)早盤升逾6% 艾伯維斥資超百億美元收購Apogee 長效AD產品獲MNC驗證","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001593","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645001593?lang=zh_tw&edition=fundamental","pubTime":"2026-06-23 09:44","pubTimestamp":1782179097,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B早盘涨超6%，截至发稿，涨6.44%，报60.35港元，成交额2624.42万港元。消息面上，艾伯维宣布拟以约109亿美金收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易预计于2026年三季度完成。国金证券指出，此次收购说明MNC对长效AD资产的战略价值和峰值销售潜力给予厚望，长效AD产品价值进一步获得MNC验证。若临床数据可支持延长给药间隔，其长效优势有望显著提升其市场竞争力。除了CM512外，公司年内仍有多项催化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1574","AD","BK4132","BK4588","BK4585","BK1161","VXUS","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638473599","title":"美國研究綜述-阿波羅、菲利普斯66、瓦萊羅能源","url":"https://stock-news.laohu8.com/highlight/detail?id=2638473599","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638473599?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 15:32","pubTimestamp":1779780727,"startTime":"0","endTime":"0","summary":"美国研究综述-阿波罗、菲利普斯66、瓦莱罗能源路透5月26日 - 周二，华尔街证券分析师调整了多家在美国上市公司的评级和目标股价，其中包括阿波罗、菲利普斯66和瓦莱罗能源。股票条目按字母顺序排列。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nL4T4230EH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","LU0205194284.USD","BK4585","LU0456854461.SGD","PS","TDS","ALB","LU0345780950.USD","LU1206713676.USD","ALNT","IE00B19Z3581.USD","LU2095319765.USD","BK4157","LU0300736062.USD","IE00B775SV38.USD","LU1861214812.USD","BK4139","LU0630314457.HKD","BAH","CGNX","RRX","TTAN","PSX","COAG","LU1201861249.SGD","LU1169589451.USD","BK4138","BK4548","BJ","LU0980610538.SGD","LU1803068623.USD","HLIO","LU0170899867.USD","VLO","SPTX","LU0477156953.USD","LU0130517989.USD","ALBG","TKR","LU0266512127.USD","MPC","APO","LU0096364046.USD","AD","LU0266013472.USD","LU2106854487.HKD","LU0274383776.USD","BK4155","IE00BZ1G4Q59.USD","LU0266512473.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636122758","title":"腦機接口尚處早期 AD藥效待突破！下一個醫藥爆款在何處？","url":"https://stock-news.laohu8.com/highlight/detail?id=2636122758","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636122758?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 16:28","pubTimestamp":1779265680,"startTime":"0","endTime":"0","summary":"【脑机接口尚处早期 AD药效待突破！下一个医药爆款在何处？】2025年，A股医药板块上市公司交出的成绩单不可谓不亮眼。然而，与扎实的业绩基本面形成鲜明对比的，是相关公司股价的“温吞”表现。这一“叫好不叫座”的现象，成为近期产业与投资界热议的焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605203743503958.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605203743503958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159938","BK1515","BK4132","09939","BK1161","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158584085","title":"Digitus集團一季度淨虧損46.071萬第納爾","url":"https://stock-news.laohu8.com/highlight/detail?id=1158584085","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158584085?lang=zh_tw&edition=fundamental","pubTime":"2026-05-17 14:00","pubTimestamp":1778997640,"startTime":"0","endTime":"0","summary":"5月17日 - 数字基建、数据中心与通信公司Digitus集团报告称，第一季度归属于公司的净亏损达到46.071万第纳尔。与此同时，集团当季总营业收入为670万第纳尔。\n本季度，公司持续投资于电力即服务、Digitus DC OM以及TeraScaleDC等业务领域。团队规模在地域上也有所扩张，尤其是在沙特阿拉伯市场，并且这一扩张覆盖了所有业务垂直领域。\n然而，集团第一季度的业绩受到了多重挑战的影响。持续的地区地缘政治紧张局势对运营构成了压力。此外，项目启动出现了延误，执行活动也有所放缓。供应链中断问题同样显著，具体表现为部分站点关闭、材料短缺以及价格飙升，这些因素共同影响了季度的财务表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","TDS","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707515","title":"衞材預計阿爾茨海默病突破性藥物Leqembi26財年全球銷售額將達1435億日元","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707515","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635707515?lang=zh_tw&edition=fundamental","pubTime":"2026-05-15 17:01","pubTimestamp":1778835693,"startTime":"0","endTime":"0","summary":"卫材预计，2026财年Leqembi的全球销售额将达到1435亿日元，较上一财年大幅增长63%。卫材表示，受全球老龄化需求驱动及多国获批上市影响，Leqembi在2026财年将迎来业绩爆发期，预计销售额同比激增六成以上。基于双方的合作协议，BioArctic预计在2026财年将获得约8.8亿瑞典克朗的特许权使用费收入，Leqembi目前已在包括中国、美国、日本和英国在内的53个国家获批。它是全球首款被证明能有效减缓早期阿尔茨海默病认知衰退的疗法。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZWE1ODViOTJlYWU0Yzg0YTU1MDJhZDdhZjY5ZjlmNDM0MDU5MzAwNzIw.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","LU0654597011.USD","BK4007","BK4132","LU0612318971.USD","LU0300736062.USD","BIOA","LU0612318385.USD","LU0075056555.USD","LU0498741890.SGD","LU0345780281.USD","LU0496367417.USD","AD","LU0498741114.HKD","LU0055631609.USD","LU0724618789.USD","LU1430597077.USD","SG9999001143.SGD","LU0788108826.HKD","LU0368265764.SGD","LU0345781412.USD","LU0345780521.USD","B","BK4161","LU0788109121.HKD","SG9999002521.SGD","LU0300736492.USD","LU1023059493.AUD","LU0330918003.SGD","LU0630314457.HKD","LU0345780950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635571752","title":"專訪復星國際陳啓宇：拿下AD新藥全球權益，「造船出海」正當時","url":"https://stock-news.laohu8.com/highlight/detail?id=2635571752","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635571752?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 20:22","pubTimestamp":1778761320,"startTime":"0","endTime":"0","summary":"当“借船出海”仍是中国创新药国际化主流叙事时，复星医药选择了一条少有人走的路：自己“造船”，并且邀请合作伙伴一同远航。5月13日，复星医药与韩国神经退行性疾病领域公司AriBio共同宣布，就阿尔茨海默病（AD）在研新药AR1001签署全球独家选择权协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737654670.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737654670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AD","BK1230","BK4132","00656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635718203","title":"復星醫藥加碼早期AD口服藥，董事長陳玉卿：看好AD賽道潛力，將做好全球商業化準備","url":"https://stock-news.laohu8.com/highlight/detail?id=2635718203","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635718203?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 17:58","pubTimestamp":1778752716,"startTime":"0","endTime":"0","summary":"复星医药董事长陈玉卿在5月14日向蓝鲸新闻表示，虽然目前阿尔兹海默症诊疗赛道目前处于早期阶段，但复星医药非常看好该赛道的发展潜力。AR1001作为一款口服的AD治疗药物，具备良好的患者依从性优势，潜在的全球销售峰值超50亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1778752606904452347","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK1593","BK0012","BK0196","BK1191","BK1515","02196","BK4132","BK0060","BK0239","BK0188","AD","BK0187","BK0096","600196","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}]}}